MeSH term
Frequency | Condition_Probility | Adult | 19 | 0.0 |
Aged | 15 | 0.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
Comparative Study | 10 | 0.0 |
Cytogenetic Analysis | 2 | 1.0 |
DNA Mutational Analysis | 11 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Female | 21 | 0.0 |
Humans | 50 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Male | 20 | 0.0 |
Middle Aged | 19 | 0.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 36 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Child, Preschool | 2 | 0.0 |
*Chromosomes, Human, Pair 4 | 7 | 3.0 |
Leukemia, Myeloid, Chronic/*genetics | 2 | 3.0 |
Receptors, Platelet-Derived Growth Factor/*genetics | 6 | 54.0 |
Gene Amplification/*genetics | 2 | 1.0 |
*Gene Expression Profiling | 2 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Phenotype | 3 | 0.0 |
Adolescent | 4 | 0.0 |
Child | 3 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Receptor, Platelet-Derived Growth Factor alpha/*genetics | 10 | 90.0 |
Research Support, U.S. Gov't, P.H.S. | 13 | 0.0 |
*Gene Amplification | 4 | 1.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
*Oncogenes | 2 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Piperazines/therapeutic use | 4 | 21.0 |
Pyrimidines/therapeutic use | 4 | 18.0 |
Blotting, Southern | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 7 | 0.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Piperazines/*therapeutic use | 5 | 10.0 |
Pyrimidines/*therapeutic use | 5 | 11.0 |
*Chromosome Aberrations | 2 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Exons | 6 | 0.0 |
Karyotyping | 3 | 0.0 |
Mutation, Missense | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Stromal Cells/pathology | 2 | 3.0 |
In Situ Hybridization | 2 | 0.0 |
*Mutation | 6 | 0.0 |
Proto-Oncogene Protein c-kit/*genetics | 5 | 12.0 |
Amino Acid Sequence | 5 | 0.0 |
Animals | 10 | 0.0 |
Base Sequence | 12 | 0.0 |
Hair Color/*genetics | 3 | 10.0 |
Horses/*genetics | 2 | 9.0 |
Molecular Sequence Data | 12 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
DNA Probes | 3 | 0.0 |
Species Specificity | 2 | 0.0 |
Mutation | 4 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Gastrointestinal Neoplasms/*genetics | 3 | 9.0 |
Stomach Neoplasms/*genetics/pathology | 2 | 4.0 |
Receptor, Platelet-Derived Growth Factor alpha/genetics | 3 | 30.0 |
Prognosis | 4 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
mRNA Cleavage and Polyadenylation Factors/*genetics | 2 | 100.0 |
*Chromosome Mapping | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics | 2 | 1.0 |
Proto-Oncogene Protein c-kit | 5 | 6.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
Hamsters | 3 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Neural Tube Defects/*genetics | 2 | 5.0 |
Proto-Oncogene Protein c-kit/*genetics/metabolism | 2 | 12.0 |
Receptor, Platelet-Derived Growth Factor alpha/*genetics/metabolism | 2 | 66.0 |
Genes, Structural | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Receptors, Cell Surface/*genetics | 3 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Receptors, Platelet-Derived Growth Factor | 2 | 6.0 |
Chromosomes, Human, Pair 4 | 2 | 1.0 |
Up-Regulation | 2 | 0.0 |
